Cargando…
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
SIMPLE SUMMARY: Pathological complete response (pCR) is a key outcome in locally advanced Her2+ breast cancer (BC) patients treated with anti-Her2−based neoadjuvant therapy. Several clinical and biological features may affect pCR rate, but reliable predictors are needed for clinical practice. The Hi...
Autores principales: | Krasniqi, Eriseld, Di Lisa, Francesca Sofia, Di Benedetto, Anna, Barba, Maddalena, Pizzuti, Laura, Filomeno, Lorena, Ercolani, Cristiana, Tinari, Nicola, Grassadonia, Antonino, Santini, Daniele, Minelli, Mauro, Montemurro, Filippo, Fabbri, Maria Agnese, Mazzotta, Marco, Gamucci, Teresa, D’Auria, Giuliana, Botti, Claudio, Pelle, Fabio, Cavicchi, Flavia, Cappelli, Sonia, Cappuzzo, Federico, Sanguineti, Giuseppe, Tomao, Silverio, Botticelli, Andrea, Marchetti, Paolo, Maugeri-Saccà, Marcello, De Maria, Ruggero, Ciliberto, Gennaro, Sperati, Francesca, Vici, Patrizia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563553/ https://www.ncbi.nlm.nih.gov/pubmed/36230758 http://dx.doi.org/10.3390/cancers14194835 |
Ejemplares similares
-
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020) -
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019) -
COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience
por: Barba, Maddalena, et al.
Publicado: (2021) -
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
por: Krasniqi, Eriseld, et al.
Publicado: (2022) -
Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
por: Mazzotta, Marco, et al.
Publicado: (2021)